These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


322 related items for PubMed ID: 25699098

  • 1. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.
    Ding L, Tian C, Feng S, Fida G, Zhang C, Ma Y, Ai G, Achilefu S, Gu Y.
    Theranostics; 2015; 5(4):378-98. PubMed ID: 25699098
    [Abstract] [Full Text] [Related]

  • 2. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
    Deng W, Liu J, Pan H, Li L, Zhou C, Wang X, Shu R, Dong B, Cao D, Li Q, Wang Z.
    J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S, Zhang J, Yan Y, Yao X, Fang L, Xiong H, Liu Y, Chu Q, Zhou P, Wu K.
    J Exp Clin Cancer Res; 2019 Aug 14; 38(1):355. PubMed ID: 31412896
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, Furumoto S, Onitsuka M, Omasa T, Hayashi H, Katayose Y, Unno M, Kudo T, Umetsu M, Kumagai I.
    MAbs; 2014 Aug 14; 6(5):1243-54. PubMed ID: 25517309
    [Abstract] [Full Text] [Related]

  • 8. (18)F-nanobody for PET imaging of HER2 overexpressing tumors.
    Xavier C, Blykers A, Vaneycken I, D'Huyvetter M, Heemskerk J, Lahoutte T, Devoogdt N, Caveliers V.
    Nucl Med Biol; 2016 Apr 14; 43(4):247-52. PubMed ID: 27067045
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
    Friedman M, Lindström S, Ekerljung L, Andersson-Svahn H, Carlsson J, Brismar H, Gedda L, Frejd FY, Ståhl S.
    Biotechnol Appl Biochem; 2009 Aug 21; 54(2):121-31. PubMed ID: 19492986
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
    Woitok M, Klose D, Niesen J, Richter W, Abbas M, Stein C, Fendel R, Bialon M, Püttmann C, Fischer R, Barth S, Kolberg K.
    Cancer Lett; 2016 Oct 28; 381(2):323-30. PubMed ID: 27502168
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
    Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V.
    J Nucl Med; 2013 Jun 28; 54(6):961-8. PubMed ID: 23528382
    [Abstract] [Full Text] [Related]

  • 18. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW, Deo YM.
    Cancer Res; 1997 Sep 15; 57(18):4008-14. PubMed ID: 9307286
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.